cytarabine has been researched along with piperidines in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 3 (9.09) | 18.2507 |
| 2000's | 8 (24.24) | 29.6817 |
| 2010's | 15 (45.45) | 24.3611 |
| 2020's | 6 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Freireich, EJ; Gottlieb, JA; Loo, TL; Mahagaokar, S; Rao, PN | 1 |
| Bible, KC; Kaufmann, SH | 1 |
| Geller, HM; Greene, LA; Morris, EJ; Park, DS; Shelanski, ML; Stefanis, L; Troy, CM | 1 |
| Coffey, ET; Courtney, MJ | 1 |
| Bishop, WR; Nakajima, A; Ohyashiki, K; Sumi, M; Tauchi, T | 1 |
| Allan, EK; Eaves, CJ; Elliott, MA; Godden, JL; Graham, SM; Holyoake, TL; Jørgensen, HG; Mountford, JC; Richmond, L | 1 |
| Bauer, KS; Bible, K; Briel, J; Colevas, AD; Garimella, TS; Gojo, I; Gore, SD; Greer, J; Karp, JE; Kaufmann, S; Passaniti, A; Ross, DD; Smith, BD; Tidwell, ML; Wright, JJ | 1 |
| Azzam, K; Hasmann, M; Nüssler, V; Pelka-Fleischer, R; Pogrebniak, A; Schemainda, I | 1 |
| Dombret, H; Thomas, X | 1 |
| Briel, J; Colevas, AD; Gore, SD; Greer, J; Hattenburg, C; Jones, RJ; Karp, JE; Levis, MJ; Smith, BD; Wright, JJ | 1 |
| Karp, J | 1 |
| Fathi, AT; Karp, JE | 1 |
| Alino, K; Blackford, A; Bolaños-Meade, J; Carraway, HE; Doyle, LA; Gore, SD; Greer, JM; Jones, RJ; Karp, JE; Levis, MJ; McDevitt, MA; Seung, AH; Smith, BD; Wright, JJ | 1 |
| van der Jagt, RH | 1 |
| Briel, J; Gocke, CD; Hess, AD; Kanakry, CG; Karp, JE; Kos, F; Levitsky, H; Luznik, L; Meyer, C; Smith, BD; Thoburn, C | 1 |
| Alino, K; Bagain, L; Blackford, A; Briel, J; Carraway, H; Doyle, LA; Gore, SD; Greer, JM; Joseph, B; Karp, JE; Levis, MJ; Mackey, K; McDevitt, MA; Moton-Nelson, D; Resar, LS; Rudek, MA; Smith, BD; Wright, JJ; Zhao, M | 1 |
| Carraway, HE; Dorcy, KS; Doyle, LA; Drye, DM; Estey, EH; Garrett-Mayer, E; Gladstone, DE; Gore, SD; Greer, JM; Karp, JE; Levis, MJ; Mackey, K; McDevitt, MA; Othus, M; Pagel, JM; Pratz, KW; Rudek, MA; Showel, MM; Smith, BD; Wright, JJ | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Liu, K; Lu, W; Wang, W; Zhang, Y | 1 |
| Blackford, AL; Bose, P; Doyle, LA; Foster, MC; Gocke, CD; Gojo, I; Karp, JE; Lancet, JE; Levy, MY; Little, RF; Litzow, MR; Morris, LE; Rosner, GL; Smith, BD; Strickland, SA; Tibes, R; Wright, JJ; Zeidner, JF | 2 |
| Gronda, M; Hurren, R; Minden, MD; Rotin, LE; Schimmer, AD; Slassi, M; Wang, X | 1 |
| Cheah, CY; Seymour, JF; Wang, ML | 1 |
| Abarrategi, A; Blackwood, E; Bonnet, D; Di Tullio, A; Grey, W; Gribben, J; Mian, S; Rouault-Pierre, K; Stewart, A | 1 |
| Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y | 1 |
| Cortes, JE; Graef, T; Jonas, BA; Luan, Y; Stein, AS | 1 |
| Bonaldi, L; Branca, A; Gurrieri, C; Manni, S; Martines, A; Piazza, F; Pizzi, M; Riva, M; Scapinello, G; Semenzato, G; Trentin, L; Visentin, A | 1 |
| Hosono, N; Negoro, E; Nishi, R; Okura, M; Shigemi, H; Yamauchi, T | 1 |
| Arasaretnam, A; Bishton, M; Bolam, S; Creasey, T; Crosbie, N; Dawi, S; Dutton, D; Eyre, TA; Follows, G; Goradia, H; Harrison, S; Johnston, R; Kirkwood, AA; Lambert, J; Lewis, D; McCulloch, R; McKay, P; McMillan, A; Miles, O; Osborne, W; Patmore, R; Phillips, N; Robinson, A; Rule, S; Wilson, MR | 1 |
| Anantha, M; Bally, MB; Chen, KTJ; Leung, AWY; Militao, GGC; Witzigmann, D | 1 |
| Anthony, S; Bearss, D; Bergua Burgues, JM; Bhatnagar, B; Bhatt, VR; Castillo, TBD; Dalovisio, A; Dillon, R; Douglas Smith, B; Esteve, J; Fine, G; Frankfurt, O; Lee, DJ; Lin, TL; Litzow, MR; Mehta, P; Montesinos, P; Nazha, A; Schriber, J; Vicente, MV; Vigil, CE; Wang, ES; Yair Levy, M; Yee, K; Zeidner, JF | 1 |
| Badillo, M; Fayad, L; Feng, L; Flowers, CR; Fowler, N; Hagemeister, FB; Hill, HA; Iyer, SP; Jain, P; Jorgensen, J; Kanagal-Shamanna, R; Lee, HJ; Li, S; Lin, P; Medeiros, LJ; Nair, R; Nastoupil, L; Navsaria, L; Nogueras Gonzalez, GM; Ok, CY; Patel, KP; Samaniego, F; Santos, D; Steiner, R; Tang, G; Thirumurthi, S; Vega, F; Wagner-Bartak, N; Wang, L; Wang, ML; Wang, SA; Westin, JR; Xu, G; Xuelin, H; Yao, Y; Yin, CC; Zhao, S | 1 |
3 review(s) available for cytarabine and piperidines
| Article | Year |
|---|---|
Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cell Cycle; Child; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Flavonoids; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Middle Aged; Piperidines; Premedication; Prognosis; Rats; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2007 |
New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.
Topics: Acute Disease; Anthracyclines; Antineoplastic Agents; Apoptosis; Cell Cycle; Cytarabine; Flavonoids; Humans; Leukemia, Myeloid; Piperidines | 2009 |
Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cytarabine; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Rituximab; Thalidomide; Transplantation, Autologous | 2016 |
11 trial(s) available for cytarabine and piperidines
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cattle; Cell Proliferation; Cohort Studies; Cytarabine; Endothelium, Vascular; Female; Flavonoids; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; U937 Cells; Vascular Endothelial Growth Factor A | 2005 |
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Flavonoids; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Piperidines; Prognosis; Remission Induction; Salvage Therapy; Survival Rate | 2007 |
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Flavonoids; Follow-Up Studies; Heart Diseases; Humans; Hyperkalemia; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Polyamines; Premedication; Remission Induction; Risk; Sepsis; Sevelamer; Transplantation, Homologous; Treatment Outcome; Tumor Lysis Syndrome; Young Adult | 2010 |
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Humans; Infusion Pumps; Leukemia; Male; Middle Aged; Mitoxantrone; Piperidines; Young Adult | 2011 |
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Flavonoids; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Survival Rate | 2012 |
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Flavonoids; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Survival Rate | 2015 |
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Flavonoids; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Risk Factors | 2018 |
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome | 2019 |
Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Non-Randomized Controlled Trials as Topic; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Survival Rate | 2019 |
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Female; Flavonoids; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myeloid Cell Leukemia Sequence 1 Protein; Piperidines | 2021 |
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Lymphopenia; Methotrexate; Middle Aged; Piperidines; Rituximab; Thrombocytopenia; Treatment Outcome; Vincristine | 2022 |
19 other study(ies) available for cytarabine and piperidines
| Article | Year |
|---|---|
Schedule-dependent synergistic cytotoxicity of arabinofuranosylcytosine with adriamycin or 3,6-bis(5-chloro-2-piperidinyl)-2,5-piperazinedione in cultured cells.
Topics: Cell Division; Cells, Cultured; Cytarabine; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Melphalan; Piperazines; Piperidines | 1975 |
Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carmustine; Cisplatin; Cyclin-Dependent Kinases; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Synergism; Etoposide; Flavonoids; Fluorouracil; Humans; Lung Neoplasms; Paclitaxel; Piperidines; Tumor Stem Cell Assay | 1997 |
Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress.
Topics: Animals; Antimetabolites, Antineoplastic; Aphidicolin; Apoptosis; Aspartic Acid; Cell Division; Cell Survival; Cyclin-Dependent Kinases; Cysteine Endopeptidases; Cytarabine; DNA Damage; Enzyme Inhibitors; Flavonoids; Humans; Kinetin; Nerve Growth Factors; Neurons; Oxidative Stress; PC12 Cells; Piperidines; Purines; Rats; Rats, Sprague-Dawley; S Phase; Superior Cervical Ganglion; Superoxide Dismutase; Ultraviolet Rays | 1998 |
The mechanism of Ara-C-induced apoptosis of differentiating cerebellar granule neurons.
Topics: Androstadienes; Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzamides; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cell Differentiation; Cell Survival; Cerebellum; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Cytarabine; Enzyme Inhibitors; Flavonoids; Imatinib Mesylate; Imidazoles; Mitogen-Activated Protein Kinase 12; Mitogen-Activated Protein Kinases; Neurons; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Purines; Pyridines; Pyrimidines; Rats; Roscovitine; Signal Transduction; Stress, Physiological; Wortmannin | 1999 |
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.
Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection; Treatment Outcome; Tumor Cells, Cultured | 2003 |
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Chromones; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Morpholines; Piperazines; Piperidines; Pyridines; Pyrimidines; Rifabutin | 2005 |
Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Topics: Acrylamides; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Combinations; Humans; K562 Cells; Leukemia, Myeloid, Acute; Melphalan; Methylnitronitrosoguanidine; Monocytes; NAD; Piperidines | 2006 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Flavonoids; Follow-Up Studies; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Risk; Treatment Outcome; Tumor Lysis Syndrome | 2010 |
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cytarabine; Cytosine; Daunorubicin; Etoposide; Female; Flavonoids; Flow Cytometry; Gene Expression Profiling; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Vidarabine; Young Adult | 2011 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Mitochondrial reactive oxygen species regulate adipocyte differentiation of mesenchymal stem cells in hematopoietic stress induced by arabinosylcytosine.
Topics: Acetylcysteine; Adipocytes; Adipogenesis; Animals; Antioxidants; Cytarabine; Hematopoiesis; Humans; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Mitochondria; Organophosphorus Compounds; Oxidative Stress; Piperidines; Reactive Oxygen Species | 2015 |
Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells.
Topics: Adenine; Cytarabine; Daunorubicin; Leukemia, Myeloid, Acute; Piperidines; Pyrazoles; Pyrimidines | 2016 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Checkpoint Kinase 1; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; U937 Cells; Xenograft Model Antitumor Assays | 2017 |
A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
Topics: Abnormal Karyotype; Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Cyclin D1; Cytarabine; Drug Resistance, Neoplasm; Fatal Outcome; Gene Duplication; Genes, myc; Humans; Lymphoma, Mantle-Cell; Male; Oncogene Proteins, Fusion; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Translocation, Genetic | 2020 |
Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Clofarabine; Cytarabine; Flavonoids; Humans; Leukemia, Myeloid, Acute; Piperidines; Sulfonamides | 2020 |
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Disease Progression; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Outcome Assessment, Health Care; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Recurrence; Retrospective Studies; Rituximab; State Medicine; United Kingdom; Withholding Treatment | 2021 |
Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia.
Topics: Animals; Cytarabine; Flavonoids; Leukemia, Myeloid, Acute; Liposomes; Mice; Piperidines | 2021 |